Cognitive Science, LLC was founded in Las Vegas, Nevada in 2015 by Michael R. Drapp (CEO) and Daniel Babcock (President) to provide leading-edge workflow solutions that incorporate emerging technologies directly associated with Augmented Reality (AR), the Internet of Things (IoT), Machine/Deep Learning and Big Data (BD). Additional information may be viewed at the Cognitive Science, LLC company website: www.cogscicorp.com.
All of life’s activities can be directly reduced to workflow; a series of steps that lead to the production of the desired outcome. While any workflow can be created and managed by Cognitive Science’s system architecture; a workflow system that can manage life activities for the cognitively impaired represents a significant market opportunity while providing real-world benefits to mankind. Today, cognitive disorders are on the increase due to people living longer and the various degenerative diseases, particularly Alzheimer’s disease, are becoming pandemic worldwide. The statistics are staggering and thus present an enormous global sales opportunity for Cognitive Science, LLC. No global family will go untouched by Alzheimer’s disease; it will be pervasive within the next 13 years. The growth of Alzheimer’s disease is currently increasing at an annualized rate of 35%. Every 66 seconds an individual is diagnosed with Alzheimer’s disease in the United States and this represented over a $300 billion cost to the United States in 2018. Globally, the cost is a staggering $1.2 trillion dollars during this same time period. Announcements from Pfizer and Johnson & Johnson that they withdrew from the development and trial of dementia related drugs, due to clinical trial failures, only support Cognitive Science’s non-pharmacological-centric methodology and approach. The digital health market, where Cognitive Science’s solution resides, is currently estimated to be worth over $230 billion dollars in 2020 and investment in software and services skyrocketed in 2017 through 2019. Clearly, this market can support a large number of companies and niche market development will become a necessity. At present, Cognitive Science is the only niche company targeted within the cognitive disease solutions space and has the first mover advantage. Investment risk is significantly reduced even if a potential entrant(s) were to enter this market niche; given the size and scope of the growing market at large. The digital health market could support several companies within each target market niche; thus reducing the risk for market displacement by competitive forces. The open architecture of Cognitive Science’s approach will allow the company to capitalize on emerging digital health trends and it provides the means for the company to pivot into new development opportunities as the market matures and grows; thus ensuring longevity and a significant increase in market valuation.
Cognitive Science’s approach to technology development is based on decades of experience in the high-technology sector by Michael R. Drapp. Michael is a widely recognized expert in workflow-based solutions; having directed and managed the workflow-based initiatives of entities like Hitachi, Fujitsu and the Department of Defense. In addition, Michael’s doctoral studies at The Ohio State University developed world-class algorithms for the infusion of artificial intelligence, deep learning and decision support systems within workflow-based environments. Michael has founded eight companies in the high-technology sector that have produced over two billion dollars in aggregate revenue on a global basis. With over 40 years of high-technology development experience, Michael determined that most startup enterprises fail due to the lack of a comprehensive technology roadmap and highly flexible software/hardware architecture that permits the company to meet its current design objectives while maintaining the capability to pivot technologically as market demand and opportunities change. To this end, Cognitive Science adopted a comprehensive, Google Cloud focused, open architecture approach within its product design and developed a leading-edge, fully working prototype of SmartFlowAR. SmartFlowAR will require an additional 9 to 12 months of development time before being available for general availability (GA) release. Our current goal is to release SmartFlowAR for general availability in the first quarter of 2021. Cognitive Science will utilize both domestic and off-shore resources for the continued development of SmartFlowAR as this is deemed to be the safest and most cost effective approach.
Cognitive disorders may be characterized by the impaired ability of an individual to recall and/or successfully execute a series of tasks. Internally, the individual knows what the desired workflow outcome should be but is incapable of keeping “on task” in order to bring about the desired outcome. Breakdown in task execution can be caused by many stimuli, both internal and external, yet all breakdown results from the failure to execute the correct and optimal workflow. To the extent that optimal and accurate workflow is performed; the cognitive disease’s effects can be minimized.
Cognitive Science’s solution, SmartFlowAR, provides the capability to significantly reduce or eliminate the effects of cognitive disorders via optimization of task recognition and execution. Utilizing Augmented-Reality-based technologies and the Google Cloud platform, sequential workflow steps (tasks) are visually presented to the impaired individual via augmented-reality glasses. Creation of the workflow can originate at any source; caregiver, medical provider, family, friends, the individual or from Cognitive Science’s “best practices” workflow database. Irrespective of the workflow provider; task creation and execution is conducted the same; sequentially. The sequence of workflow tasks is created, one task at a time, either by direct voice input, icon selection or by a download from the Internet or other connected source. Once created, each task is reviewed upon execution by Artificial Intelligence (AI) logic to determine if the task was successfully completed or has an exception occurred. If completed successfully, the task is logged and workflow continues. If an exception has occurred, the impaired individual is guided through a series of resolution tasks, then workflow resumes and the completed task is logged. When all tasks are completed, the desired workflow is now complete and logged. This process is repeated for any and all workflows that have been created. In addition, if desired, variables associated with the Internet of Things (IoT) can be included with the completed workflow logging, such as WiFi and Bluetooth-enabled device readings.
The investment process can be staged to coincide with the product development cycle; thereby creating a just-in-time investment model that minimizes the upfront risk to the investor(s). The remaining product roadmap will require 9 to 12 months of additional development time and testing prior to MVP (Minimum Viable Product) availability. An initial Seed Round of investment of $2,000,000USD will be required to bring SmartFlowAR to a MVP (Minimum Viable Product) status and this entire amount must be escrowed at the time the initial investment of $1,000,000USD is made.
As is the case with any business startup, the revenue model is highly speculative. The application of augmented-reality systems to real-world operations in inevitable according to Kevin Kelly; well known futurist, editor and author of “The Inevitable”. Initial marketing research conducted by Cognitive Science, LLC yielded an extremely positive market adoption rate of greater than 85%. Given the availability of global distribution channels, and a positive adoption rate, expected revenue has been calculated to exceed $10,000,000 after a full year of SmartFlowAR market availability. Historically, the median growth rate in revenue for a technology company is 130% YoY through $25,000,000 in annualized revenue. This percentage gradually declines to around 40% YoY as annual revenue exceeds $500,000,000. Clearly, this represents an enormous rate-of-return for the early investor(s) in Cognitive Science, LLC.
If you desire additional information or an Investor Presentation, please contact Michael Drapp at or email@example.com. Michael can also be reached via phone at +1 (408) 838-4270. Please also review Cognitive Science’s website at: www.cogscicorp.com. After the execution of a mutual Non-Disclosure Agreement (NDA), Cognitive Science will be happy to provide an in-depth presentation on our SmartFlowAR product, SmartFlowAR database and our “best practices” workflow consulting capabilities.